The changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.

INTRODUCTION

The global burden of invasive fungal infections (IFIs) is increasing, with the threat of disease exacerbated by the emergence of antifungal resistance. While antifungals remain the mainstay for the treatment of IFIs, there is a growing recognition of the many patient variables, particularly in challenging situations (e.g. critically ill patients), that can impact the exposure of antifungals.

AREAS COVERED: This narrative review focuses on the changing epidemiology of Candida species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios, based on a symposium held at the International Society for Human and Animal Mycology Asia Congress in Bangkok, Thailand, on 1 August 2024.

EXPERT OPINION: Antifungal resistance is common and increasing among fungal pathogens (e.g. Candida species) in the Asia Pacific. Optimal drug selection and dosing of antifungals is critical for achieving the best therapeutic outcomes and limiting resistance emergence, particularly in challenging clinical scenarios. Current 'standard' doses of antifungals do not account for pharmacokinetic variations in critically ill patients and can lead to suboptimal exposures, highlighting the need for better dosing regimens in these patients. Therapeutic drug monitoring is a valuable strategy for optimizing antifungal therapy, and its use is encouraged, particularly in critically ill patients.